Genenta Science S.p.A. GNTA 深 滬
等待開盤 12-12 09:30:00 美东时间
1.65
-0.100
-5.71%
華盛通- 最 高1.75
- 今 開1.73
- 成交量 6.90万股
- 最 低 1.61
- 昨 收 1.75
- 總市值 3017.83万
- 52周最高 10.00
- 市盈率 靜 --
- 換手率 0.38%
- 52周最低 1.35
- 委 比 79.65%
- 總股本 1828.99万
- 歷史最高 13.13
- 量 比 1.19
- 振 幅 8.00%
- 歷史最低 1.35
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Genenta Science, a biotechnology company, reported updated results from its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter. As of November 21, 2025, 25 patients treated with Temferon showed consistent survival metrics compared to April 2025 data: 44% reached 18-month survival, 29% achieved two-year survival, and median overall survival remained at 17 months. A patient reached three...
11-24 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 18.6% to $2.1...
11-21 05:06
Genenta Science通过定向增发筹集1500万美元
美股周一早盘，临床阶段生物技术研发商Genenta Science（GNTA）股价暴跌43.4%，此前该公司宣布通过定向增发筹集1500万美元，股价交易于...
10-27 22:47
Genenta Science Appoints New Board Member and Confirms CEO
Genenta Science SpA Sponsored ADR ( ($GNTA) ) has shared an update. On April 29...
10-27 18:28
Genenta Science jumps on $15M direct offering
Genenta Science (NASDAQ:GNTA) entered into a securities purchase agreement with institutional investors to purchase 4.29M ADSs at an offering price of $3.50 per ADS, for gross proceeds of ~$15M. All o...
10-27 15:20
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
Genenta Science (Nasdaq: GNTA), a clinical-stage immuno-oncology company, has entered into a securities purchase agreement with institutional investors to sell 4,285,715 ADSs at $3.50 each, raising approximately $15 million. Proceeds will be used for working capital and corporate purposes. The offering is expected to close on October 28, 2025. Genenta is developing hematopoietic stem cell therapies for solid tumor cancers, with its lead candidate...
10-27 00:30
美股牛股 | Wellgistics Health涨185.4%；INHIBRX涨102%
Wellgistics Health涨185.4%；INHIBRX涨102.0%；Genenta Science S.p.A.涨92.0%
10-25 16:28
Market-Moving News for October 24th
INTC: 9% | Intel shares are trading higher after the company reported Q3 EPS and sales above expectations. COIN: 3% | Coinbase Global shares are trading higher after JPMorgan upgraded the stock from
10-24 19:14
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
Genenta Science and ANEMOCYTE have expanded their partnership to focus on off-the-shelf lentiviral vector plasmid DNA technology. This collaboration leverages Genenta's proven LVV platform, developed by Luigi Naldini, to enhance ANEMOCYTE's offerings across R&D to commercial stages. Both CEOs highlighted the strategic importance of this alliance for advancing therapy programs.
10-24 08:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 24.9% to $3.11 duri...
07-02 20:06
